Raymond DuBois (academic)

Last updated
Raymond N. DuBois
NationalityAmerican
Alma mater Texas A&M University
Scientific career
Fields Biochemistry and molecular biology
Institutions Vanderbilt-Ingram Cancer Center
University of Texas MD Anderson Cancer Center
Biodesign Institute

Raymond N. DuBois is an American academic and scientist. He is the incumbent director of the Hollings Cancer Center at the Medical University of South Carolina and executive chairman of the board of the Mark Foundation for Cancer Research. [1] [2] He was the president of the American Association for Cancer Research between 2008 and 2009. [3]

Contents

Early life and education

DuBois attended Texas A&M University, where he received a bachelor's degree in biochemistry. [3] [4] Later, he joined a medical school, University of Texas School of Medicine, and completed a medical degree. [3] [4] He also holds a doctorate degree in biochemistry from the University of Texas. [3] [4]

Career

From 1991 to 2007, he was the director of the Vanderbilt-Ingram Cancer Center. [5] [6]

Between 2007 and 2012, DuBois was the provost and executive vice president of the University of Texas MD Anderson Cancer Center. [7] He also held the Ellen Knisely Distinguished Chair in colon cancer research. [8] [3]

In 2012, he joined the Biodesign Institute at Arizona State University as the executive director and served until 2016. [6] [8]

In March 2016, DuBois became the dean of the College of Medicine at the Medical University of South Carolina. [3] [6]

In 2019, he was elected to the National Academy of Medicine. [6]

In 2020, he was appointed as the director of Hollings Cancer Center. [6] [9]

In February 2022, he was appointed as the executive chairman of the board of Mark Foundation for Cancer Research. [2]

Research

DuBois is known for his research on the causes of cancer, its spread, and what prevents it. [6]

DuBois co-invented a method for identifying and targeting cellular genes required for viral development, as well as cellular genes that act as tumour suppressors in mammals. [10]

Awards and recognition

Bibliography

Related Research Articles

<span class="mw-page-title-main">Medical University of South Carolina</span> Public medical school in Charleston, South Carolina, US

The Medical University of South Carolina (MUSC) is a public medical school in Charleston, South Carolina. It opened in 1824 as a small private college aimed at training physicians and has since established hospitals and medical facilities across the state. It is one of the oldest continually operating schools of medicine in the United States and the oldest in the Deep South.

<span class="mw-page-title-main">The Biodesign Institute</span> Research center at Arizona State University

The Biodesign Institute is a major research center known for nature-inspired solutions to global health, sustainability, and security challenges located on the Tempe campus of Arizona State University. The institute is organized into a growing number of collaborative research centers and laboratories staffed by scientists in diverse disciplines. It is currently led by Executive Director Dr. Joshua LaBaer, a personalized diagnostics researcher.

<span class="mw-page-title-main">Emil Frei</span> American physician and oncologist

Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.

Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300. Colditz was a member of the Institute of Medicine Committee to Review Adverse Effects of Vaccines but resigned, along with Ruby H. N. Nguyen, before it produced its seminal report.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

<span class="mw-page-title-main">Charles Sawyers</span> American physician-scientist (born 1959)

Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.

<span class="mw-page-title-main">Aviv Regev</span> Bioinformatician

Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.

Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.

Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.

Richard David Kolodner is an American scientist with Ludwig Cancer Research who has made research contributions to the genetic basis for inherited susceptibility to common cancers. He is a Distinguished Professor of Cellular and Molecular Medicine at the UC San Diego School of Medicine. Kolodner is a member of the National Academy of Sciences and National Academy of Medicine, and he is a fellow of the American Academy of Arts and Sciences.

Owen Witte is an American physician-scientist at the University of California, Los Angeles. He is a University Professor of microbiology, immunology and molecular genetics in the David Geffen School of Medicine at UCLA, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the UC Regents’ David Saxon Presidential Chair in developmental immunology (1989–present). Witte is also a Howard Hughes Medical Institute investigator (1986–2016) and a member of the President's Cancer Panel, the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Cancer Research Academy of the AACR. He serves on numerous editorial boards and scientific advisory boards for academic centers and biotechnology companies.

Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.

David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana–Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.

Charles J. Sherr is the chair of the Tumor Cell Biology Department at St. Jude Children's Research Hospital. He studies tumor suppressor genes and cell division.

Scott M. Lippman is the former Director of Moores Cancer Center at the University of California, San Diego and current Professor of Medicine at UC San Diego School of Medicine.

<span class="mw-page-title-main">Daniel Von Hoff</span> American oncologist

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.

<span class="mw-page-title-main">Curtis C. Harris</span> American cancer researcher

Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.

Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.

<span class="mw-page-title-main">Chanita Hughes-Halbert</span> American psychologist and medical researcher

Chanita Ann Hughes-Halbert is an American psychologist and medical researcher. She is professor of psychiatry and behavioral sciences at the Medical University of South Carolina and the AT&T Distinguished Endowed Chair for Cancer Equity at the Hollings Cancer Center. She is the first woman and first African American from South Carolina elected to the National Academy of Medicine.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

References

  1. 1 2 "MUSC Hollings Cancer Center director receives AACR Distinguished Service Award".
  2. 1 2 "The Mark Foundation for Cancer Research appoints Raymond N. DuBois as executive chairman". The Post and Courier . 21 February 2022.
  3. 1 2 3 4 5 6 "Raymond N. DuBois - MUSC Health Charleston SC".
  4. 1 2 3 4 5 6 7 "Raymond N. DuBois Receives Landon Prize". Journal of Investigative Medicine . ProQuest   2032729005 . Retrieved 2022-06-29.
  5. "DuBois picked to lead". The Tennessean .
  6. 1 2 3 4 5 6 "DuBois named director of MUSC Hollings Cancer Center". Charleston Business Journal. 13 August 2020.
  7. "LOCAL BUSINESS. Director to leave Vanderbilt-Ingram". The Tennessean .
  8. 1 2 "AACR Congratulates Dr. Raymond N. DuBois on His Appointment as Executive Director of Arizona State University's Biodesign Institute". ProQuest   1095454901.
  9. "Dr. Raymond DuBois appointed director of MUSC Hollings Cancer Center". Beckers Hospital Review. 27 July 2020.
  10. "Inflammation and Inflammatory Mediators as Potential Targets for Cancer Prevention or Interception". Cancer Prevention Fellowship Program.